Opinion|Videos|July 23, 2024
Expert Insights for Long-Term Treatment Planning in CLL
Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss considerations for long-term treatment planning in CLL, examining various treatment sequences and associated advantages and tradeoffs.
- How do you approach long-term treatment planning?
- Do you factor in potential 2L+ treatment options at the 1L stage?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Five Under 5: Top Oncology Videos for the Week of 8/16
4
The OncFive: Top Oncology Articles for the Week of 8/16
5